Plasma proteins, metabolites, and platelet changes in extracorporeal CPR for cardiac arrest patients

Explore Plasma Biomarkers and Platelet Morphological Signatures for Predicting Prognosis in Patients With Extracorporeal CardioPulmonary Resuscitation (ECPR) Using Multi-omics and Platelet Morphology Analysis

This project will test whether patterns in blood proteins, small molecules, and platelet shape changes can help identify which adults with cardiac arrest might benefit from extracorporeal CPR.

Quick facts

• Study type: Observational
• Enrollment: 130 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Central China Fuwai Hospital of Zhengzhou University (Academic / other)
• Locations: 1 site (Zhengzhou, Henan)
• Trial ID: NCT07113769 on ClinicalTrials.gov

What this trial studies

This is an observational study collecting plasma proteomic and metabolomic data plus detailed platelet ultrastructure from adults with refractory cardiac arrest treated with extracorporeal cardiopulmonary resuscitation (ECPR). Samples and platelet imaging will be obtained before and after ECPR to look for reproducible molecular and morphological markers. The goal is to find markers that predict which patients with reversible causes of arrest are most likely to benefit from ECPR. The work is being conducted at Central China Fuwai Hospital with regional hospital collaborators.

Who should consider this trial

Good fit: Adults (typically 18–70 years) with witnessed refractory cardiac arrest who receive immediate bystander CPR, have potentially reversible causes, and meet local ECPR eligibility are the ideal candidates.

Not a fit: Patients with un-witnessed arrests, long delays to CPR, active infectious or hematologic disease, or non-reversible causes of arrest are unlikely to gain benefit from the markers targeted in this project.

Why it matters

Potential benefit: If successful, clinicians could use blood- and platelet-based markers to better select cardiac arrest patients for ECPR, improving outcomes and avoiding futile interventions.

How similar studies have performed: Some prior work has explored biomarkers in ECMO and cardiac arrest, but reliable proteomic/metabolomic or platelet-structure predictors for selecting ECPR candidates remain largely unproven and this approach is relatively novel.

Eligibility criteria

Inclusion Criteria:

1. Age between 18 and 70 years old (the age limit can be relaxed if the patient has good organ function and a good neurological prognosis after evaluation).
2. The cardiac arrest is witnessed, and bystanders perform traditional cardiopulmonary resuscitation (CPR), and the time interval from the occurrence of cardiac arrest to the start of traditional CPR is no more than 5 minutes.
3. The causes of cardiac arrest are reversible, such as cardiogenic, pulmonary embolism, severe hypothermia, drug poisoning, trauma, acute respiratory distress syndrome, etc.
4. After 20 minutes of traditional CPR, there is no restoration of spontaneous circulation or hemodynamic instability, or the restoration of spontaneous circulation occurs, but the spontaneous heart rhythm cannot be maintained.
5. The informed consent has been signed.

Exclusion Criteria:

1. Infectious diseases, such as hepatitis B, hepatitis C, AIDS, syphilis, etc.
2. Hematological diseases, such as hematological malignancies, aplastic anemia, idiopathic thrombocytopenic purpura (ITP), etc.
3. Malignant tumors in other systems except the hematological system.
4. Patients who have received massive plasma or platelet transfusions during hospitalization or recently.

Where this trial is running

Zhengzhou, Henan

• Fuwai Central China Cardiovascular Hospital — Zhengzhou, Henan, China (Recruiting)

Study contacts

• Study coordinator: Jianchao Li

Conditions ExtraCorporeal Membrane Oxygenation; Cardiac Arrest